| 1 |
Vincent JL，Castro P，Hunt BJ，et al.Thrombocytopenia in the ICU：disseminated intravascular coagulation and thrombotic microangiopathies—what intensivists need to know[J]．Crit Care，2018，22(1)：158.
|
| 2 |
Zarychanski R，Houston DS.Assessing thrombocytopenia in the intensive care unit：the past，present，and future[J]．Hematology Am Soc Hematol Educ Program，2017，2017(1)：660-666.
|
| 3 |
Iba T，Levy JH，Raj A，et al.Advance in the management of sepsis- induced coagulopathy and disseminated intravascular coagulation[J]．J Clin Med，2019，8(5)：728.
|
| 4 |
Thiolliere F，Serre-Sapin AF，Reignier J，et al.Epidemiology and outcome of thrombocytopenic patients in the intensive care unit：results of a prospective multicenter study[J]．Intensive Care Med，2013，39(8)：1460-1468.
|
| 5 |
中国临床肿瘤学会肿瘤化疗所致血小板减少症共识专家委员会．肿瘤化疗所致血小板减少症诊疗中国专家共识(2018版)[J]．中华肿瘤杂志，2018，40(9)：714-720.
|
| 6 |
中国临床肿瘤学会(CSCO)抗白血病联盟，中国临床肿瘤学会(CSCO)抗淋巴瘤联盟．急性白血病化疗所致血小板减少症诊疗中国专家共识[J]．白血病·淋巴瘤，2019，28(4)：193-197.
|
| 7 |
中华医学会血液学分会止血与血栓学组．成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J]．中华血液学杂志，2016，37(2)：89-93.
|
| 8 |
Menard CE，Kumar A，Houston DS，et al.Evolution and impact of thrombocytopenia in septic shock：a retrospective cohort study[J]．Crit Care Med，2019，47(4)：558-565.
|
| 9 |
Thachil J．Disseminated intravascular coagulation：a practical approach[J]．Anesthesiology，2016，125(1)：230-236.
|
| 10 |
Alhamdi Y，Abrams ST，Lane S，et al.Histone-associated thrombocytopenia in patients who are critically ill[J]．JAMA，2016，315(8)：817-819.
|
| 11 |
Charri A，Medhioub F，Samet M，et al.Thrombocytopenia in critically ill patients：a review of the literature[J]．Anaesth Crit Care Pain Med，2011，1(4)：199-202.
|
| 12 |
Chang JC.Disseminated intravascular coagulation：is it fact or fancy？[J]．Blood CoagulFibrinolysis，2018，29(3)：330-337.
|
| 13 |
Gando S，Levi M，Toh CH.Disseminated intravascular coagulation[J]．Nat Rev Dis Primers，2016，2：16037.
|
| 14 |
Levi M，Scully M．How I treat disseminated intravascular coagulation[J]．Blood，2018，131(8)：845-854.
|
| 15 |
Warkentin TE.Heparin-induced thrombocytopenia in critically ill patients[J]．Semin Thromb Hemost，2015，41(1)：49-60.
|
| 16 |
Fuchs TA，Bhandari AA，Wagner DD.Histones induce rapid and profound thrombocytopenia in mice[J]．Blood，2011，118(13)：3708- 3714.
|
| 17 |
Thiery-Antier N，Binquet C，Vinault S，et al.Is thrombocytopenia an early prognostic marker in septic shock[J]? Crit Care Med，2016，44(4)：764-772.
|
| 18 |
Menard CE，Kumar A，Houston DS，et al.Evolution and impact of thrombocytopenia in septic shock：a retrospective cohort study[J]．Crit Care Med，2019，47(4)：558-565.
|
| 19 |
Xie Y，Tian R，Xie H，et al.The clinical significance of thrombocytopenia complicating sepsis：a meta-analysis[J]．J Infect，2019，78(4)：323-337.
|
| 20 |
Claushuis TA，van Vught LA，Scicluna BP，et al.Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients[J]．Blood，2016，127(24)：3062-3072.
|
| 21 |
Moreau D，Timsit JF，Vesin A，et al.Platelet count decline：an early prognostic marker in critically ill patients with prolonged ICU stays[J]．Chest，2007，131(6)：1735-1741.
|
| 22 |
Venkata C，Kashyap R，Farmer JC，et al.Thrombocytopenia in adult patients with sepsis：incidence，risk factors，and its association with clinical outcome[J]．J Intensive Care，2013，1(1)：9.
|
| 23 |
Akca S，Haji-Michael P，de MendoncaA，et al.Time course of platelet counts in critically ill patients[J]．Crit Care Med，2002，30(4)：753- 756.
|
| 24 |
Durila M，Kalincik T，Jurcenko S，et al.Arteriovenous differences of hematological and coagulation parameters in patients with sepsis[J]．Blood CoagulFibrinolysis，2010，21(8)：770-774.
|
| 25 |
Ostrowski SR，Windelov NA，Ibsen M，et al.Consecutive thrombelastography clot strength profiles in patients with severe sepsis and their association with 28-day mortality：a prospective study[J]．J Crit Care，2013，28(3)：311-317.
|
| 26 |
Muzaffar SN，Baronia AK，Azim A，et al.Thromboelastography for evaluation of coagulopathy in nonbleeding patients with sepsis at intensive care unit admission[J]．Indian J Crit Care Med，2017，21(5)：268-273.
|
| 27 |
Saini A，Spinella PC，Ignell SP，et al.Thromboelastography variables，immune markers，and endothelial factors associated with shock and NPMODS in children with severe sepsis[J]．Front Pediatr，2019，7：422.
|
| 28 |
Massion PB，Peters P，Ledoux D，et al.Persistent hypocoagulability in patients with septic shock predicts greater hospital mortality：impact of impaired thrombin generation[J]．Intensive Care Med，2012，38(8)：1326-1335.
|
| 29 |
Sivula M，Pettila V，Niemi TT，et al.Thromboelastometry in patients with severe sepsis and disseminated intravascular coagulation[J]．Blood CoagulFibrinolysis，2009，20(6)：419-426.
|
| 30 |
Brenner T，Schmidt K，Delang M，et al.Viscoelastic and aggregometric point-of-care testing in patients with septic shock - cross-links between inflammation and haemostasis[J]．Acta Anaesthesiol Scand，2012，56(10)：1277-1290.
|
| 31 |
Stanworth SJ，Navarrete C，Estcourt L，et al.Platelet refractoriness-- practical approaches and ongoing dilemmas in patient management[J]．Br J Haematol，2015，171(3)：297‐305.
|
| 32 |
Moncharmont P．Platelet component transfusion and alloimmunization：Where do we stand？[J]．Transfus Clin Biol，2018，25(3)：172‐ 178.
|
| 33 |
Warner MN，Moore JC，Warkentin TE，et al.A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura[J]．Br J Haematol，1999，104(3)：442‐447.
|
| 34 |
Hagenström H，Schlenke P，Hennig H，et al.Quantification of platelet-associated IgG for differential diagnosis of patients with thrombocytopenia[J]．Thromb Haemost，2000，84(5)：779‐783.
|
| 35 |
Yang YF.Analysis of the correlations between immunological changes and syndrome groups in patients with immunological thrombocytopenic purpura(ITP)[J]．Zhongguo Zhong Xi Yi Jie He Za Zhi，1992，12(5)：263‐259.
|
| 36 |
Ware R，Kinney TR，Friedman HS，et al.Prognostic implications for direct platelet-associated IgG in childhood idiopathic thrombocytopenic purpura[J]．Am J Pediatr Hematol Oncol，1986，8(1)：32‐37.
|
| 37 |
Lassila R．Platelet function tests in bleeding disorders[J]．Semin Thromb Hemost，2016，42(3)：185-190.
|
| 38 |
许晓巍，李岩，贡伟，等．脓毒症凝血功能异常的发生率和临床意义[J]．临床急诊杂志，2010，11(4)：232-233，236.
|
| 39 |
Asakura H，Takahashi H，Uchiyama T，et al.Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis[J]．Thromb J，2016，14：42.
|
| 40 |
Yamakawa K，Umemura Y，Murao S，et al.Optimal timing and early intervention with anticoagulant therapy for sepsis-induced disseminated intravascular coagulation[J]．Clin Appl Thromb Hemost，2019，25：1076029619835055.
|
| 41 |
Iba T，Nisio MD，Levy JH，et al.New criteria for sepsis-induced coagulopathy(SIC)following the revised sepsis definition：a retrospective analysis of a nationwide survey[J]．BMJ Open，2017，7(9)：e017046.
|
| 42 |
Machlus KR，Thon JN，Italiano JE Jr.Interpreting the developmental dance of the megakaryocyte：a review of the cellular and molecular processes mediating platelet formation[J]．Br J Haematol，2014，165(2)：227-236.
|
| 43 |
Zang C，Luyten A，Chen J，et al.NF-E2，FLI1 and RUNX1 collaborate at areas of dynamic chromatin to activate transcription in mature mouse megakaryocytes[J]．Sci Rep，2016，6：30255.
|
| 44 |
Roweth HG，Parvin S，Machlus KR.Megakaryocyte modification of platelets in thrombocytopenia[J]．Curr Opin Hematol，2018，25(5)：410-415.
|
| 45 |
Decousus H，Tapson VF，Bergmann JF，et al.Factors at admission associated with bleeding risk in medical patients：findings from the IMPROVE investigators[J]．Chest，2011，139(1)：69-79.
|
| 46 |
Rosenberg D，Eichorn A，Alarcon M，et al.External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism(IMPROVE)for medical patients in a tertiary health system[J]．J Am Heart Assoc，2014，3(6)：e001152.
|
| 47 |
Hostler DC，Marx ES，Moores LK，et al.Validation of the international medical prevention registry on venous thromboembolism bleeding risk score[J]．Chest，2016，149(2)：372-379.
|
| 48 |
Greinacher A，Selleng S．How I evaluate and treat thrombocytopenia in the intensive care unit patient[J]．Blood，2016，128(26)：3032-3042.
|
| 49 |
Droege CA，Ernst NE，Messinger NJ，et al.Evaluation of Thrombocytopenia in critically ill patients receiving continuous renal replacement therapy[J]．Ann Pharmacother，2018，52(12)：1204-1210.
|
| 50 |
Ferreira JA，Johnson DW.The incidence of thrombocytopenia associated with continuous renal replacement therapy in critically ill patients[J]．Ren Fail，2015，37(7)：1232-1236.
|
| 51 |
Guru PK，Singh TD，Akhoundi A，et al.Association of thrombocytopenia and mortality in critically ill patients on continuous renal replacement therapy[J]．Nephron，2016，133(3)：175-182.
|
| 52 |
Warkentin TE，Levine MN，Hirsh J，et al.Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin[J]．N Engl J Med，1995，332(20)：1330-1335.
|
| 53 |
Lefrançais E，Ortiz-Muñoz G，CaudrillierA，et al.The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors[J]．Nature，2017，544(7648)：105-109.
|
| 54 |
Zhang J，Lu Z，Xiao W，et al.Efficacy and safety of recombinant human thrombopoietin on sepsis patients with thrombocytopenia：a systematic review and meta-analysis[J]．Front Pharmacol，2020，11：940.
|
| 55 |
Wu Q，Ren J，Wu X，et al.Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia：a prospective study[J]．J Crit Care，2014，29(3)：362-366.
|
| 56 |
章渭方，方君俊，王国彬，等．重组人血小板生成素治疗脓毒症相关血小板减少症患者的临床研究[J/CD]．中华危重症医学杂志(电子版)，2016，9(5)：300-308.
|
| 57 |
Wang B，Yao F，Wang Y，et al.A multi-center clinical observation of recombinant human thrombopoietin for the treatment of sepsis- associated thrombocytopenia[J]．Int J Clin Exp Med，2019，12(5)：6324-6334.
|
| 58 |
Zhou Z，Feng T，Xie Y，et al.The effect of recombinant human thrombopoietin(rhTPO)on sepsis patients with acute severe thrombocytopenia：a study protocol for a multicentre randomised controlled trial(RESCUE trial)[J]．BMC Infect Dis，2019，19(1)：780.
|
| 59 |
中国老年医学学会，国家老年疾病临床医学研究中心(解放军总医院)，解放军老年医学专业委员会．感染诱发的老年多器官功能障碍综合征诊断与治疗中国指南2019[J]．中华老年多器官疾病杂志，2019，18(11)：801-838.
|
| 60 |
Kaushansky K．Thrombopoietin[J]．N Engl J Med，1998，339(11)：746-754.
|
| 61 |
Wan B，Zhang H，Fu H，et al.Recombinant human interleukin-11(IL-11)is a protective factor in severe sepsis with thrombocytopenia：a case- control study[J]．Cytokine，2015，76(2)：138-143.
|
| 62 |
Tepler I，E1ias L，Hussein M，et al.A randomized placebo controlled trial of recombinant human intedeukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy[J]．Blood，1996，87(9)：3607-3614.
|
| 63 |
Isaacs C，Robert NJ，Bailey FA，et al.Randomized placebo controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin[J]．J Clin Oncol，1997，15(11)：3368-3377.
|
| 64 |
Polovich M，Whitford JM，olsen M，et al.Chemotherapy and biotherapy guidelines and recommendations for practice[M].4th ed.Oncology Nursing Society，2014.
|
| 65 |
Jin C，Wang Y，Cheng H，et al.Platelet and peripheral white blood cell counts at diagnosis predict the response of adult immune thrombocytopenia to recombinant human interleukin-11：A retrospective，single-center，case-control study[J]．Medicine(Baltimore)，2019，98(16)：e15195
|
| 66 |
Wand S，Klages M，Kirbach C，et al.IgM-enriched immunoglobulin attenuates systemic endotoxin activity in early severe sepsis：a before- after cohort study[J]．PLoS One，2016，11(8)：e0160907.
|
| 67 |
Blumberg N，Cholette JM，Schmidt AE，et al.Management of Platelet Disorders and Platelet Transfusions in ICU Patients[J]．Transfus Med Rev，2017，31(4)：252-257.
|
| 68 |
Ning S，Barty R，Liu Y，et al.Platelet Transfusion Practices in the ICU：Data From a Large Transfusion Registry[J]．Chest，2016，150(3)：516- 523.
|
| 69 |
Bjursten H，Al-Rashidi F，DardashtiA，et al.Risks associated with the transfusion of various blood products in aortic valve replacement[J]．Ann Thorac Surg，2013，96(2)：494-499.
|
| 70 |
Stanworth SJ，Walsh TS，Prescott RJ，et al.Thrombocytopenia and platelet transfusion in UK critical care：a multicenter observational study[J]．Transfusion，2013，53(5)：1050-1058.
|
| 71 |
World Health Organization.WHO Handbook for Reporting Results of Cancer Treatment[J]．WHO offset publication，1979，48：22-28.
|
| 72 |
Estcourt LJ，Birchall J，Allard S，et al.Guidelines for the use of platelet transfusions[J]．Br J Haematol，2017，176(3)：365-394.
|
| 73 |
Kaufman RM，Djulbegovic B，Gernsheimer T，et al.Platelet transfusion：a clinical practice guideline from the AABB[J]．Ann Intern Med，2015，162(3)：205-213.
|
| 74 |
Estcourt LJ，Birchall J，Lowe D，et al.Platelet transfusions in haematology patients：are we using them appropriately？[J]．Vox Sang，2012，103(4)：284-293.
|
| 75 |
Rhodes A，Evans LE，Alhazzani W，et al.Surviving Sepsis Campaign：International Guidelines for Management of Sepsis and Septic Shock：2016[J]．Intensive Care Med，2017，43(3)：304-377.
|
| 76 |
Wandt H，Schäfer-Eckart K，Greinacher A．Platelet transfusion in hematology，oncology and surgery[J]．Dtsch Arztebl Int，2014，111(48)：809-815.
|
| 77 |
Zeidler K，Arn K，Senn O，et al.Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia[J]．Transfusion，2011，51(11)：2269-2276.
|
| 78 |
Estcourt LJ，Malouf R，Doree C，et al.Prophylactic platelet transfusions prior to surgery for people with a low platelet count[J]．Cochrane Database Syst Rev，2018，9(9)：CD012779.
|
| 79 |
Warner MA，Chandran A，Frank RD，et al.Prophylactic platelet transfusions for critically ill patients with thrombocytopenia：a single- institution propensity-matched cohort study[J]．Anesth Analg，2019，128(2)：288-295.
|
| 80 |
Triulzi DJ，Assmann SF，Strauss RG，et al.The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding inpatients with hypoproliferative thrombocytopenia[J]．Blood，2012，119(23)：5553-5562.
|
| 81 |
Estcourt LJ，Stanworth S，Doree C，et al.Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation[J]．Cochrane Database Syst Rev，2015，10(10)：CD010984.
|
| 82 |
Kerrigan SW.The expanding field of platelet-bacterial interconnections[J]．Platelets，2015，26(4)：293-301.
|
| 83 |
Larkin CM，Santos-Martinez MJ，Ryan T，et al.Sepsis-associated thrombocytopenia[J]．Thromb Res，2016，141：11-16.
|
| 84 |
Greco E，Lupia E，Bosco O，et al.Platelets and multi-organ failure in sepsis[J]．Int J Mol Sci，2017，18(10)：2200.
|
| 85 |
Aubron C，Flint AW，Bailey M，et al.Is platelet transfusion associated with hospital-acquired infections in critically ill patients？[J]．Crit Care，2017，21(1)：2.
|
| 86 |
Haesebaert J，Bénet T，Michallet M，et al.Septic shock during platelet transfusion in a patient with acute myeloid leukaemia[J]．BMJ Case Rep，2013，2013：bcr2013010412.
|
| 87 |
Katus MC，Szczepiorkowski ZM，Dumont LJ，et al.Safety of platelet transfusion：past，present and future[J]．Vox Sang，2014，107(2)：103-113.
|
| 88 |
Saini A，West AN，Harrell C，et al.Platelet Transfusions in the PICU：Does Disease Severity Matter？[J]．Pediatr Crit Care Med，2018，19(9)：e472-e478.
|
| 89 |
Kaufman RM，Assmann SF，Triulzi DJ，et al.Transfusion-related adverse events in the Platelet Dose study[J]．Transfusion，2015，55(1)：144-153.
|
| 90 |
Kumawat V，Sharma RR，Malhotra P，et al.Prevalence of risk factors for platelet transfusion refractoriness in multitransfused hemato- oncological patients at tertiary care center in North India[J]．Asian J Transfus Sci，2015，9(1)：61-64.
|
| 91 |
Ferreira AA，Zulli R，Soares S，et al.Identification of platelet refractoriness in oncohematologic patients[J]．Clinics(Sao Paulo)，2011，66(1)：35-40.
|